The antiserum was produced against synthesized peptide derived from human PIAS1.
Alternative Names:
AR interacting protein,DDXBP1,DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1,DEAD/H box-binding protein 1,E3 SUMO-protein ligase PIAS1,E3 SUMO-protein transferase PIAS1,GBP,GU/RH-II,gu-binding protein,protein inhibitor of activated STAT protein 1,RNA helicase II-binding protein,zinc finger, MIZ-type containing 3,ZMIZ3.
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. Sumoylates PML (atLys-65 and Lys-160) and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity).
